Kidney Cancer Diagnosis
Kidney Cancer Diagnosis
Diagnosing kidney cancer is largely a matter of imaging, and the imaging has to be done in a particular way to answer the questions that matter. The scan must show how the mass takes up contrast, how large it is, whether it has grown into the vein draining the kidney, and whether anything has spread. A biopsy adds the subtype and grade when that will change what is done, and blood tests establish how much kidney function there is to work with.
The scan, and why it must be multiphasic
The single most useful test in kidney cancer is a CT scan of the abdomen performed with intravenous contrast, in several phases. Each phase answers a different question, which is why a single unenhanced scan or a plain ultrasound cannot substitute for it:
- Before contrast — establishes the baseline and identifies calcification.
- Arterial phase — shows how richly the mass takes up blood, which is the feature that separates most kidney cancers from benign lesions.
- Nephrographic phase — the phase in which the tumour is seen most clearly against normal kidney tissue, and the one on which the size and position of the tumour are decided for surgical planning.
- Excretory phase — shows the collecting system and confirms that the other kidney drains normally, which matters before any operation on one side.
MRI is used in specific situations rather than as a routine alternative: when contrast cannot be given because of allergy or poor kidney function, when a tumour extending into the renal vein or the large vein above it needs to be characterised precisely, and in some patients where the CT appearance is inconclusive. A chest scan is added to look for spread, because the lungs are a common site.
One practical instruction follows: send the original images, not only the written report. A report gives conclusions, whereas the questions that decide treatment — how close the tumour is to the collecting system, how much normal kidney would remain after removal, how far a venous thrombus extends — are answered by looking at the images. This is the commonest reason a remote assessment comes back asking for more material.
When a biopsy is needed, and when it is not
A renal mass biopsy takes a small sample of tissue with a needle, under imaging guidance. It is not needed for every mass, and the decision follows a clear logic rather than a routine:
- Not needed when a mass has the typical enhancing appearance of a cancer and the plan is surgery anyway — the operation will provide the whole specimen, and a biopsy would add risk without changing what happens.
- Needed when the mass is indeterminate — the appearance does not settle whether it is a cancer, a benign tumour or something else such as a lymphoma or an infection.
- Needed before ablation or surveillance — because the technique that destroys tissue, or the decision to leave it alone, depends on knowing what the tissue is.
- Needed before systemic treatment for advanced disease — where the subtype and grade determine the drugs, and treating with the wrong regimen costs time that cannot be recovered.
Two qualifications need stating. A biopsy may fail to give a diagnosis — too little tissue in the sample, or only normal kidney — and when that happens the usual response is a repeat biopsy rather than pressing ahead with an operation on an unclear picture. And because the sample is small, the grade it reports may differ from the grade of the whole tumour: a biopsy reported as low grade does not guarantee that the whole tumour is low grade. Both points mean the biopsy is read alongside the imaging rather than instead of it.
Grading: the number that predicts behaviour
Grading describes how abnormal the cells look under the microscope, and in kidney cancer it is reported with the WHO/ISUP nucleolar grade, numbered 1 to 4, based largely on how prominent the nucleoli are. It is a separate axis from staging: stage says where the tumour is, grade says how aggressive it is likely to be.
Three points make the grade actionable:
- It changes follow-up. A grade 3 or 4 tumour removed at an early stage is followed more closely than a grade 1 tumour of the same size, because the risk of recurrence differs.
- It helps identify who benefits from treatment after surgery. The decision to offer an immune checkpoint inhibitor after an operation for high-risk disease depends on a combination of stage, grade and other features rather than size alone.
- It is not interchangeable between subtypes. Chromophobe tumours are graded by different criteria from clear cell and papillary tumours, which is why a grade should always be read together with the subtype rather than on its own.
The last point is the one patients most often need to hear. A grade reported for a chromophobe tumour is not the same yardstick as a grade reported for a clear cell tumour, and comparing the two leads to the wrong conclusion. A pathology report that states the subtype and the grade together, and names the grading system used, is the version worth having.
Staging: how far it reaches
Staging uses the AJCC system and rests on three findings from the scan: how far the tumour has grown into or beyond the kidney, whether lymph nodes are involved, and whether there is spread elsewhere. The features that most often change management are the less obvious ones:
- Size within the kidney. The 4 cm line separates tumours that are usually straightforward to remove with the kidney preserved from those where the decision is more finely balanced.
- Extension into the renal vein or the large vein above it. This is described as a venous thrombus, and it is not the same as spread: such tumours can still be removed completely, but the operation has to be planned around the vein.
- Invasion of the fat around the kidney or the adrenal gland. This changes the stage and makes the case for discussing treatment after surgery.
- Lymph nodes. Node involvement moves the disease into a group where systemic treatment becomes part of the plan.
- Distant spread. The lungs, bone, liver and brain are the sites to look for, which is why a chest scan is part of staging.
There is one staging step patients rarely anticipate. In advanced disease the classification that is actually used clinically is not the stage number but the IMDC risk group, calculated from six routine measures: performance status, the interval from diagnosis to starting treatment, haemoglobin, corrected calcium, neutrophil count and platelet count. That calculation decides whether first-line treatment is an immunotherapy combination or a single targeted agent. It also explains why the blood tests requested before an assessment are not a formality — several of them are the inputs to this score.
Kidney function, measured before it matters
Because a person has two kidneys and needs only part of one to survive, the amount of filtering capacity that will remain after treatment is a central part of planning, not an afterthought. Two measurements carry the weight: creatinine, and the estimated glomerular filtration rate calculated from it along with age and sex.
These numbers change the plan in four ways:
- They push toward preserving kidney. When function is already reduced, removing an entire kidney may tip a patient toward needing dialysis, so partial nephrectomy is pursued even when it is technically harder.
- They constrain the drugs that can be used. Certain agents are unsuitable when filtration is poor, which is a reason to know the value before systemic treatment rather than after.
- They affect whether contrast can be given. Poor function may make MRI the better imaging choice, or require precautions if contrast is used.
- They set a baseline to protect. Function is rechecked after treatment, and the aim is to keep it stable, which is why controlling blood pressure and avoiding unnecessary kidney-damaging medicines are part of the plan.
The practical instruction is simple: bring the most recent creatinine result. It is the single value patients most often leave out when sending records abroad, and the one that most often changes which route is possible.
Turning the findings into a plan
Once the scan, the pathology and the blood results are assembled, the assessment has to answer four interlocking questions:
- What is the subtype and grade? — established from the surgical specimen, or from a biopsy where one is indicated; this decides whether the subtype-specific options apply.
- How far has it reached? — confined to the kidney, into the vein or surrounding fat, into nodes, or beyond, with a chest scan completed.
- How much kidney will remain? — the decision between preserving and removing the organ, made from the scan and the creatinine result together.
- Which routes the findings actually support? — surveillance, ablation, partial nephrectomy or radical nephrectomy for localised disease, with systemic treatment added where the stage and risk group call for it.
These questions are interdependent, which is why a written assessment should answer them as a set and state plainly which single missing item would change the recommendation. That is precisely what a records review produces, and it is why sending the images, the pathology and the blood results together returns a more useful answer than sending them one at a time.